CX Institutional’s Madrigal Pharmaceuticals MDGL Stock Holding History

CX Institutional’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1K	Hold	2	–	–	﹤0.01%	1534
2026 Q1	$1K	Hold	2	–	–	﹤0.01%	1519
2025 Q4	$1K	Buy	+2	New	+$1.02K	﹤0.01%	1472

Other funds holding MDGL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

CX Institutional's MDGL Position: Q2 2026 in Review

CX Institutional held its Madrigal Pharmaceuticals (MDGL) position steady in Q2 2026 at 2 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #1534.

CX Institutional first reported a position in MDGL in Q4 2025 and has held it in 3 quarters since. 414 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

CX Institutional held 2 shares of Madrigal Pharmaceuticals worth $1K as of Q2 2026.
CX Institutional left its Madrigal Pharmaceuticals share count unchanged in Q2 2026.
Madrigal Pharmaceuticals made up ﹤0.01% of CX Institutional's portfolio in Q2 2026, its #1534 holding.
CX Institutional first reported a position in Madrigal Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
414 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on CX Institutional's 13F filing for Q2 2026, filed 2 Jul 2026.